Pirepemat

N/A

Report date: 2022/12/17 23:45:54
NME

Base Information

Drug NamePirepemat
Drug Alias NameIRL-752
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCentral nervous system stimulantsAlpha adrenergic receptor antagonistsSerotonin 7 (5-HT7) receptor antagonists
TargetsAlpha adrenergic receptorSerotonin 7 (5-HT7) receptor
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenPolandNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntegrative Research Laboratories Ab
China Registration ClassN/A

Develop Information

Active CompaniesIntegrative Research Laboratories Ab
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A